Cubist Pharmaceuticals is set to buy Adolor in a cash and shares deal that could total up to $415 million, according to a Genetic Engineering and Biotechnology News report.
The deal will allow Cubist to obtain Entereg, an oral, peripherally acting mu opioid receptor antagonist. The drug is the only FDA-approved treatment for speeding upper and lower gastrointestinal recovery time following partial large or small bowel resection surgery with primary anastomosis.
Related Articles on Pain Management:
Adaptation to Upright Walking Leaves Humans Susceptible to Backbone Fractures, Pain
Researchers to Study 'Scrambler Therapy' for Pain Relief
Chronic Pain Care for Women Cost $12.9 Billion in 2008
The deal will allow Cubist to obtain Entereg, an oral, peripherally acting mu opioid receptor antagonist. The drug is the only FDA-approved treatment for speeding upper and lower gastrointestinal recovery time following partial large or small bowel resection surgery with primary anastomosis.
Related Articles on Pain Management:
Adaptation to Upright Walking Leaves Humans Susceptible to Backbone Fractures, Pain
Researchers to Study 'Scrambler Therapy' for Pain Relief
Chronic Pain Care for Women Cost $12.9 Billion in 2008